NCT05325684 2022-04-13PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung CancerThe Affiliated Hospital of Qingdao UniversityPhase 1/2 Unknown30 enrolled